Abstract
Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 499-502 |
| Number of pages | 4 |
| Journal | Transplantation Proceedings |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2009 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Transplantation
Cite this
Alemtuzumab : Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? / Schneeberger, S.; Landin, L.; Kaufmann, C.; Gorantla, V. S.; Brandacher, G.; Cavadas, P.; Lee, W. P A; Breidenbach, Warren C; Margreiter, R.
In: Transplantation Proceedings, Vol. 41, No. 2, 03.2009, p. 499-502.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alemtuzumab
T2 - Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?
AU - Schneeberger, S.
AU - Landin, L.
AU - Kaufmann, C.
AU - Gorantla, V. S.
AU - Brandacher, G.
AU - Cavadas, P.
AU - Lee, W. P A
AU - Breidenbach, Warren C
AU - Margreiter, R.
PY - 2009/3
Y1 - 2009/3
N2 - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
AB - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
UR - http://www.scopus.com/inward/record.url?scp=62849099728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62849099728&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2009.01.018
DO - 10.1016/j.transproceed.2009.01.018
M3 - Article
C2 - 19328912
AN - SCOPUS:62849099728
VL - 41
SP - 499
EP - 502
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 2
ER -